Thermo Fisher Launches Automated System to Streamline Cell Therapy Manufacturing

Key Facts

1Thermo Fisher Scientific launched the Gibco™ CTS™ Compleo™ system to automate formulation and filling in cell therapy manufacturing.

2The system aims to reduce manual intervention and enhance consistency in manufacturing outcomes.

3The system is designed to maintain sterility and dose accuracy as cell therapies move toward commercialization.

Thermo Fisher Scientific has introduced the Gibco CTS Compleo system, a functionally closed and automated solution designed for the fill and finish stages of cell therapy production. The new system aims to significantly reduce manual intervention, thereby enhancing consistency and precision in manufacturing outcomes. By maintaining strict sterility and dose accuracy, the system addresses critical requirements as cell therapies transition toward large-scale commercialization. This launch is specifically intended to tackle the challenges of variability inherent in patient-derived therapies, streamlining the path to market. The introduction of this technology strengthens Thermo Fisher's competitive position within the high-growth cell and gene therapy sector. Furthermore, the automation of these processes is expected to improve operational efficiency for biotech firms scaling their production capabilities.